Search
Ranibizumab
go.drugbank.com/drugs/DB01270ApprovedInvestigationalBYOOVIZ, a biosimilar of LUCENTIS, was approved by Health Canada in March 2022, making it the first and only biosimilar drug of ranibizumab available in Canada. … [A246399] Ranibizumab was initially approved by the FDA in 2006 [A2301] and by the European Commission (EC) in 2007.[L41429] It is marketed under the brand names LUCENTIS and SUSVIMO.
Tocofersolan
go.drugbank.com/drugs/DB11635ApprovedD-Alpha-tocopheryl polyethylene glycol 1000 succinate (Tocofersolan, Vedrop), has been developed in Europe as an orally bioavailable source of vitamin E in children suffering from cholestasis [L2371]. … Tocofersolan is a polyethylene glycol derivative of α-tocopherol and synthetic water-soluble version of [DB11251].
Mixtures: Pre-Tabs DHA Prenatal Multi-vitamin/Mineral Supplement with DHA/EPA, NESTABS ABC Prenatal Multi-vitamin/Mineral Supplement with DHA/EPACategories: Compounds used in a research, industrial, or household settingPergolide
go.drugbank.com/drugs/DB01186ApprovedVet approvedWithdrawnThe drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007. … It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors.
Products: PERGOLIDE MYLAN GENERICSChondroitin sulfate
go.drugbank.com/drugs/DB09301ApprovedInvestigationalNutraceutical[A32063] Chondroitin sulfate is sold as an OTC dietary supplement in North America and it is a prescription drug under the EMA in Europe.[A32066] … Chondroitin sulfate is composed of alternating 1,3-N-acetyl-β-d-galactosamine and 1,4-β-d-glucuronic acid units which bear 4-O- and/or 6-O-sulfations at the N-acetylgalactosamine units disposed of in specific
Mixtures: GLUCONITRIN D, GLUCONITRIN DCertolizumab pegol
go.drugbank.com/drugs/DB08904ApprovedInvestigational[A176606] It was developed and manufactured by UCB Pharma, first FDA approved in 2008[L45018] and updated for a new indication on March 28, 2019.[L5819] … [A176585] It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region.
Levodopa
go.drugbank.com/drugs/DB01235ApprovedInvestigationalThe first developed drug product that was approved by the FDA was a levodopa and carbidopa combined product called Sinemet that was approved on May 2, 1975[A177781,L6133]. … Levodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier[Label].
Mixtures: Aa-levocarb CR, Aa-levocarb CRParathyroid hormone
go.drugbank.com/drugs/DB05829ApprovedInvestigationalPreotact is used in the treatment of osteoporosis in postmenopausal women at high risk of osteoporotic fractures and is marketed in Europe by Nycomed. … , leaving the mature protein as a single-chain 84 amino-acids polypeptide (9.4 kDa).
Clofedanol
go.drugbank.com/drugs/DB04837ApprovedWithdrawnClofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States.
Mixtures: Atuss Da, Atuss DaTepotinib
go.drugbank.com/drugs/DB15133ApprovedInvestigationalIn February 2022, tepotinib was approved for use in Europe.[L42200] … Tepotinib was first approved in Japan in March 2020 for the treatment of non-small cell lung cancers (NSCLC) with _MET_ alterations, and was subsequently granted accelerated approval by the US FDA in February
Maribavir
go.drugbank.com/drugs/DB06234ApprovedInvestigationalDNA polymerase-based therapies, and their use is often limited by toxicities like myelosuppression and renal injury. … [L39322] Most standard CMV therapies, such as [ganciclovir] or [foscarnet], target CMV DNA polymerase - while generally effective, these medications tend to promote the development of CMV resistance to